The Science of Addiction in 2026: What We Actually Know
Addiction is a brain disease, genetics matter, and the science is moving faster than most clinicians can keep up with.
Body: [Draft covers: brain-disease model (mesolimbic dopamine, prefrontal control), genetic contribution (~50%), adolescent vulnerability, stress-relapse cycle, evidence for MAT, psychedelics renaissance (MDMA, psilocybin, ibogaine research), neuromodulation (TMS), digital therapeutics, and the NIH HEAL Initiative’s ~$500M/year investment. Clear disclaimer: brain-disease model doesn’t erase personal agency — it explains why willpower alone is insufficient.]
Related: Psychedelics research in 2026 | TMS for addiction — what the evidence says | “Addiction is a brain disease” — what that actually means.
Sources Cited
- 01.A
- 02.Ahttps://heal.nih.govNIH HEAL Initiative
Filed Under
Peer-Reviewed ResearchMAT — BuprenorphineFederal
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.